°íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå(2024-2034³â)
Highly Potent Active Pharmaceutical Ingredients (HPAPIs) Market Report 2024-2034
»óǰÄÚµå : 1503263
¸®¼­Ä¡»ç : Visiongain
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 335 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¡Ì 4,350 £Ü 8,442,000
Unprintable PDF (Single User) - 1 Year License help
º¸°í¼­ PDF¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ) ÀåÂø PDF(ÀÌ¿ë±â°£Àº ±¸¸ÅÀϷκÎÅÍ 1³â)·Î Á¦°øµÇ¸ç, ÀÎÁõµÈ PC 1´ë¿¡¼­¸¸ ¿­¶÷ °¡´ÉÇÕ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ì 5,150 £Ü 9,995,000
PDF (Team License - Up to 6 Users) - 1 Year License help
º¸°í¼­ PDF¸¦ µ¿ÀÏ »ç¾÷Àå(¼ÒÀçÁö) ³»ÀÇ 6¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ³» ÅØ½ºÆ® µîÀÇ Copy&Paste´Â ºÒ°¡´ÉÇÕ´Ï´Ù. DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ) ÀåÂø PDF(ÀÌ¿ë±â°£Àº ±¸¸ÅÀϷκÎÅÍ 1³â)À̸ç, ÀÎÁõµÈ PC»ó¿¡¼­ ¿­¶÷ °¡´ÉÇÕ´Ï´Ù. Àμâ´Â 1¸í´ç 1ȸ¸¸ °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
¡Ì 6,050 £Ü 11,742,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1¸í´ç 1ȸ¸¸ °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
¡Ì 7,645 £Ü 14,837,000
PDF (Enterprise License - Includes Free Datasets) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö CAGR 9.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁø :

¾Ï, ½ÉÇ÷°üÁúȯ, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ µîÀÇ ¸¸¼ºÁúȯÀº Àå±âÀûÀÎ Ä¡·á¿Í Áö¼ÓÀûÀÎ °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´À» °ü¸®Çϱâ À§ÇÑ È¿°úÀûÀÎ ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ôÀ¸¸ç, HPAPI´Â È¿´É°ú ƯÁ¤ Áúº´ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï´Â ´É·ÂÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ¾à¹°¿¡ ÇʼöÀûÀ̸ç, HPAPI´Â Ç¥Àû Ä¡·áÁ¦ ¹× »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº ÷´Ü Ä¡·áÁ¦¸¦ ¸¸µå´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Á¾¾ç ºÐ¾ß¿¡¼­ HPAPI´Â °Ç°­ÇÑ Á¶Á÷¿¡ ÇØ¸¦ ³¢Ä¡Áö ¾ÊÀ¸¸é¼­ ¾Ï¼¼Æ÷¸¦ ÆÄ±«ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá È­Çпä¹ý ¹× Ç¥ÀûÄ¡·áÁ¦¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç¥ÀûÈ­µÈ Á¢±Ù¹ýÀº ¸¸¼ºÁúȯÀ» È¿°úÀûÀ¸·Î °ü¸®Çϰí Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Á¦¾à»çµéÀº ¸¸¼ºÁúȯÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ½Å¾àÀ» °³¹ßÇϱâ À§ÇØ R&D¿¡ Áö¼ÓÀûÀ¸·Î ÀÚ¿øÀ» ÅõÀÔÇϰí ÀÖ½À´Ï´Ù. Àú¿ë·®À¸·Î ³ôÀº È¿´ÉÀ» ¹ßÈÖÇÏ´Â °í¾à¸®È°¼º¿ø·á(HPAPI)´Â ÀÌ·¯ÇÑ Á¦Á¦¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí Ä¡·á¸¦ º¸´Ù ½±°Ô °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. HPAPI´Â Æò»ý ¾à¹° Ä¡·á°¡ ÇÊ¿äÇÑ ¸¸¼ºÁúȯ ȯÀڵ鿡°Ô Ä¡·á È¿°ú¸¦ ¿¬ÀåÇϰí, Åõ¿© Ƚ¼ö¸¦ ÁÙÀ̸ç, Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ¾à¹°ÀÇ °³¹ßÀ» ÃËÁøÇÕ´Ï´Ù.

ºñ°¨¿°¼º Áúȯ(NCD)¿¡ ÀÇÇØ ¸Å³â 4,100¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖÀ¸¸ç, À̰ÍÀº ¼¼°è Àüü »ç¸ÁÀÚ ¼öÀÇ 74%¿¡ »ó´çÇÕ´Ï´Ù. ¸Å³â 1,700¸¸ ¸íÀÌ 70¼¼±îÁö NCD·Î »ç¸ÁÇϰí ÀÖÀ¸¸ç, ÀÌ Áß 86%°¡ ÁßÀú¼Òµæ±¹¿¡¼­ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

³ôÀº Á¦Á¶ ºñ¿ëÀÌ »ê¾÷ ¼ºÀåÀÇ ¹æÇذ¡ µÉ °¡´É¼ºÀÌ ³ô´Ù. :

HPAPIÀÇ Á¦Á¶¿¡´Â ¾ÈÀü¼º°ú ±ÔÁ¦ Áؼö¸¦ È®º¸Çϱâ À§ÇØ Æ¯¼öÇÑ ½Ã¼³, ¼³ºñ, °Ý³³ ½Ã½ºÅÛ¿¡ °Å¾×ÀÇ ÀÚº» ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº Ãʱ⠺ñ¿ë°ú Áö¼ÓÀûÀÎ ¿î¿µ ºñ¿ëÀº Áß¼Ò±â¾÷ ½ÃÀå ÁøÀÔÀ» ¸·°Å³ª ±âÁ¸ ±â¾÷ÀÇ »ý»ê ´É·Â È®ÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖÀ¸¸ç, HPAPI Á¦Á¶¿¡´Â ³ôÀº È¿´É°ú ¼øµµ¸¦ À¯ÁöÇϸ鼭 ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇÑ º¹ÀâÇϰí Á¤¹ÐÇÑ °øÁ¤ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ °øÁ¤Àº ÷´Ü ±â¼ú, ¼÷·ÃµÈ ÀηÂ, ¾ö°ÝÇÑ Ç°Áú°ü¸® Á¶Ä¡°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ ¸ðµç °ÍÀÌ Á¦Á¶ ºñ¿ë »ó½ÂÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸÀÇ ºÐ¼®, ½ÃÀå ±Ô¸ðÀÇ ÃßÀÌ¡¤¿¹Ãø, °¢Á¾ ±¸ºÐ¡¤Áö¿ª/ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸®Æ÷Æ® °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : Á¦Ç°º°

Á¦5Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : Á¦Á¶¾÷ü À¯Çüº°

Á¦6Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : ¾àÁ¦ À¯Çüº°

Á¦7Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : Á¦Çüº°

Á¦8Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦9Àå °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå ºÏ¹ÌÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼®

Á¦11Àå À¯·´ÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼®

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼®

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼®

Á¦14Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °íÈ¿´É ¿ø·áÀǾàǰ(HPAPI) ½ÃÀå ºÐ¼®

Á¦15Àå ±â¾÷ °³¿ä

Á¦16Àå °á·Ð¡¤Á¦¾È

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Highly Potent Active Pharmaceutical Ingredients Market is Projected to Grow at a CAGR of 9.6% by 2034

The Highly Potent Active Pharmaceutical Ingredients (HPAPIs) Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Incidence of Chronic Diseases Driving Market Growth

Chronic illnesses, including cancer, cardiovascular conditions, diabetes, and autoimmune disorders, necessitate prolonged treatment and ongoing management. The demand for effective medications to manage these conditions is high, and HPAPIs are often integral to these medications due to their potency and ability to target specific disease pathways. HPAPIs play a vital role in creating advanced treatments, such as targeted therapies and biologics. In the field of oncology, for example, HPAPIs are utilized in chemotherapeutic drugs and targeted treatments that focus on destroying cancer cells while reducing harm to healthy tissue. This targeted approach is essential for effectively managing and treating chronic diseases. Pharmaceutical companies are consistently pouring resources into research and development to develop new medications that can effectively manage chronic diseases. High Potency Active Pharmaceutical Ingredients (HPAPIs) are vital in these formulations, providing high efficacy at lower doses. This approach not only enhances patient outcomes but also minimizes side effects, making treatments more manageable. For patients with chronic illnesses who need lifelong medication, HPAPIs facilitate the creation of drugs that offer prolonged therapeutic effects, decrease dosing frequency, and improve adherence to treatment regimens.

Non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from a NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries.

High Manufacturing Costs Likely to Hamper Industry Growth

Manufacturing HPAPIs requires substantial capital investment in specialized facilities, equipment, and containment systems to ensure safety and regulatory compliance. These high initial and ongoing operational costs can deter smaller companies from entering the market or limit the ability of existing companies to expand their production capacities. The production of HPAPIs involves complex and precise processes to maintain high potency and purity while ensuring safety. These processes often require advanced technology, skilled personnel, and stringent quality control measures, all of which contribute to higher manufacturing costs.

What Questions Should You Ask before Buying a Market Research Report?

How is the highly potent active pharmaceutical ingredients market evolving?

What is driving and restraining the Highly potent active pharmaceutical ingredients Market?

How will each highly potent active pharmaceutical ingredients submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each highly potent active pharmaceutical ingredients submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading highly potent active pharmaceutical ingredients markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the highly potent active pharmaceutical ingredients projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of highly potent active pharmaceutical ingredients projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the highly potent active pharmaceutical ingredients market?

Where is the highly potent active pharmaceutical ingredients market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Highly Potent Active Pharmaceutical Ingredients Market today, and over the next 10 years:

Our 335-page report provides 124 tables and 220 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising highly potent active pharmaceutical ingredients prices and recent developments.

Segments Covered in the Report

Product

Synthetic

Biotech

Manufacturer Type

In-house

Outsource

Drug Type

Innovative

Generic

Dosage Form

Solids

Liquids

Injectable

Others

Application

Oncology

Hormonal Imbalance

Glaucoma

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles for some of the leading companies in the Highly Potent Active Pharmaceutical Ingredients Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Bayer AG

Boehringer Ingelheim International GmbH

Bristol Myers Squibb Company

Cambrex Corporation

Catalent, Inc

Cipla Inc.

Dr Reddy's Laboratories

Eli Lilly and Company

F. Hoffmann-La Roche AG

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Sanofi

Teva Pharmaceutical Industries Ltd.

Overall world revenue for Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 in terms of value the market will surpass US$29,600 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 report help you?

In summary, our 330+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034, with forecasts for product, manufacturer, drug type, dosage form, and application each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

2 Executive Summary

3 Market Overview

4 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Product

5 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Manufacturer Type

6 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Drug Type

7 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Dosage Form

8 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Application

9 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Region

10 North America Highly Potent Active Pharmaceutical Ingredients Market Analysis

11 Europe Highly Potent Active Pharmaceutical Ingredients Market Analysis

12 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Analysis

13 Latin America Highly Potent Active Pharmaceutical Ingredients Market Analysis

14 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Analysis

15 Company Profiles

16 Conclusion and Recommendations

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â